Related references
Note: Only part of the references are listed.Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells
Qin He et al.
CANCER BIOLOGY & THERAPY (2010)
Downregulation of nuclear factor-κB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer
Rui Kong et al.
CANCER LETTERS (2010)
Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo
Shuang-Jia Wang et al.
CANCER LETTERS (2010)
Proteasome Inhibitor MG132 Inhibits Angiogenesis in Pancreatic Cancer by Blocking NF-κB Activity
Yoichi Matsuo et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-κB
Hua Chen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo
Hua Chen et al.
ANTI-CANCER DRUGS (2009)
Experimental therapy of hepatoma with artemisinin and its derivatives:: In vitro and in vivo activity, chemosensitization, and mechanisms of action
Junmei Hou et al.
CLINICAL CANCER RESEARCH (2008)
The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells
Deguang Mu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone: Implications for embryotoxicity
Sarah D'Alessandro et al.
TOXICOLOGY (2007)
Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice
Toru Nakamura et al.
NEOPLASIA (2007)
Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells
Hui-Jun Zhou et al.
VASCULAR PHARMACOLOGY (2007)
Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1α activation in C6 glioma cells
Xiao-Jia Huang et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2007)
Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells
T Efferth
CURRENT DRUG TARGETS (2006)
Platelet-activating factor induces matrix metalloproteinase-9 expression through Ca2+- or PI3K-dependent signaling pathway in a human vascular endothelial cell line
HM Ko et al.
FEBS LETTERS (2005)
Antimalarial dihydroartemisinin also inhibits angiogenesis
HH Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Nf-κb activity blockade impairs the angiogenic potential of human pancreatic cancer cells
HQ Xiong et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate
R Dell'Eva et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro
HH Chen et al.
PHARMACOLOGICAL RESEARCH (2003)
Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer
S Liptay et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Mechanism and its regulation of tumor-induced angiogenesis
MK Gupta et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2003)
The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies
M Wartenberg et al.
LABORATORY INVESTIGATION (2003)
Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis
JG Rozic et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
G Bergers et al.
NATURE CELL BIOLOGY (2000)